| University of Antwerp

Vibeke Kruse unpaid guest prof. Publications Vibeke Kruse A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced $BRAF^{V600}$ mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors Sour…

Strictly necessary cookies

They are necessary for the proper functioning of the website and can not be switched off. They are generally defined only as a result of actions you carry out and that enable you to make use of the services we offer (definition of your privacy preferences, connection, filling in forms, etc.). You can configure your browser so that these cookies are blocked or you are warned about these cookies, but then some parts of the site will no longer work.

Statistical cookies

They allow us to measure surfing patterns and determine which sections of our website were visited, and to measure habits and improve our services. They show us which pages are the most and the least popular and how visitors move around the site. If you do not allow these cookies, we do not know when you visited our site and we can not check their habits.

Personalization cookies

They enable improved functionality and customization of the site. They can be activated by us or by third parties whose services we have added to our pages. If you do not allow these cookies, some or all of the services may not work properly.

Targeted cookies

They can be set up by our advertising partners on our site to build a profile of your interests and show you relevant ads on other sites. They do not store personal information directly, but are based on the unique identification of your browser and device. If you do not allow these cookies, you will see less targeted ads.

1 results found

Publications Vibeke Kruse | Vibeke Kruse | University of Antwerp

Cookie prreferences